

1-1-2021

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lungadenocarcinomas?

PINAR BULUTAY

PINAR FIRAT

EMİNE HANDAN ZEREN

SUAT ERUS

SERHAN TANJU

See next page for additional authors

Follow this and additional works at: <https://journals.tubitak.gov.tr/medical>



Part of the [Medical Sciences Commons](#)

Recommended Citation

BULUTAY, PINAR; FIRAT, PINAR; ZEREN, EMİNE HANDAN; ERUS, SUAT; TANJU, SERHAN; and DİLEGE, MUSTAFA ŞÜKRÜ (2021) "The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lungadenocarcinomas?," *Turkish Journal of Medical Sciences*: Vol. 51: No. 1, Article 26. <https://doi.org/10.3906/sag-2004-61>

Available at: <https://journals.tubitak.gov.tr/medical/vol51/iss1/26>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lungadenocarcinomas?

Authors

PINAR BULUTAY, PINAR FIRAT, EMİNE HANDAN ZEREN, SUAT ERUS, SERHAN TANJU, and MUSTAFA ŞÜKRÜ DİLEGE

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Pınar BULUTAY^{1*}, Pınar FIRAT¹, Handan ZEREN², Suat ERUS³, Serhan TANJU³, Şükrü DİLEGE³

¹Department of Pathology, Medical Faculty, Koç University, İstanbul, Turkey

²Department of Pathology, Medical Faculty, Acıbadem University, İstanbul, Turkey

³Department of Thoracic Surgery, Medical Faculty, Koç University, İstanbul, Turkey

Received: 06.04.2020 • Accepted/Published Online: 05.11.2020 • Final Version: 26.02.2021

Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC).

Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed.

Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns.

Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.

Key words: PD-L1, lung cancer, immunotherapy, lung adenocarcinoma

1. Introduction

Lung cancer is the leading cause of cancer related mortality worldwide and one of the most highly mutated ones among solid tumors. Many lung cancer patients have a high mutational burden [1]. Nonsmall cell lung cancer (NSCLC) accounts for the majority of lung cancer cases (80%-85%) [2,3]. Most patients have locally advanced or metastatic disease on initial presentation. In the past, the treatment options for advanced or metastatic disease were typically confined to chemotherapy or radiation therapy, but the advent of targeted therapies as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) inhibitors have led to improved outcome in some patients who harbor driver oncogenes, especially in lung adenocarcinomas [4,5].

Recently immunotherapy represented a new and highly promising therapeutic option for metastatic

NSCLCs on first and second-line therapy. Several approved immunotherapeutic drugs, such as pembrolizumab, avelumab, and nivolumab are being used on the 'programmed cell death-ligand 1 (PD-L1) positive ($\geq 1\%$) cases. Guidelines for NSCLC treatment emphasizes the importance of PD-L1 expression levels for optimal use of antiPD1/PD-L1 therapies with or without chemotherapeutic agents. Single-agent pembrolizumab can be used in NSCLC patients with PD-L1 expression higher than 50% in tumor cells [6].

PD-L1 is a transmembrane protein and normally expressed on the antigen-presenting cells and also some tumor cells [7-9]. It is one of the most important immune-inhibitory checkpoints, and it can stop or limit the development of the T-cell response through binding to its inhibitory receptor, programmed death-1 (PD1). PD1 is an inhibitory receptor located on the surface of activated T,

* Correspondence: pbulutay@kuh.ku.edu.tr

B, and natural killer cells [10,11]. An interaction between the PD1 receptor and PD-L1 leads to inhibition of primary T-cell proliferation response and cytolytic activity against the tumor antigens and protects the tumor cells from the antitumor immune response. At this point, the immune checkpoint inhibitors, against either PD1 or PD-L1 and reactivate the immune system and tumor cells become visible again [12].

PD-L1 immunohistochemistry (IHC) is an established method for testing intratumoral PD-L1 expression in daily practice [13]. However, it has some difficulties. The biggest obstacle is PD-L1 can show heterogeneous expression, so IHC results can lead to false negative results, especially on small biopsy specimens [14–20].

In this study, we retrospectively analyzed the PD-L1 expression of resected lung adenocarcinomas and analyzed the importance of histological patterns on heterogeneous expression with the microarray technique.

2. Materials and methods

This study comprises 128 lung adenocarcinoma cases that had undergone surgery at the Koç University Hospital and the American Hospital (Turkey) between 2011 and 2017. Clinical and pathological data were recorded using electronic medical files and pathology reports. The hematoxylin and eosin (H&E) stained slides were retrieved from the pathology archives and reviewed by two expert pulmonary pathologists (PB and PF). All samples were reclassified and restaged according to 2015 WHO classification and TNM staging (8th edition) for lung carcinomas [21].

Two separate tumor areas were selected in a 4 mm diameter on H&E-stained slides and removed from the corresponding areas of paraffin-blocks for tissue microarray (TMA) construction. We selected one core from the dominant pattern and the other from the high-grade pattern, if present. Nine of the cases were studied only on one core because of the tumor size. Totally 16 new TMA paraffin blocks were constructed. Two unstained sections were taken from the paraffin blocks, one of them was stained with H&E and the other stained with PD-L1 IHC. Histological patterns were evaluated of each tissue cores independently. The lepidic, papillary, and acinar patterns were recorded as low/intermediate grade, and the solid, micropapillary patterns, and mucinous adenocarcinomas were recorded as high grade [22,23].

2.1. Immunohistochemistry

Immunohistochemistry on TMA sections was carried out with an automated stainer (Ventana Benchmark (Tucson, AZ) using antiPD-L1 (SP142) with optiview detection kit, obtained from Roche (Arizona, USA). Tissue samples were considered adequate for evaluation if the tissue samples were had more than 100 tumor cells and classified

as positive if the expression was seen in at least 1% of tumor cells with complete circumferential or partial linear membranous staining at any intensity [24].

2.2. PD-L1 scoring

PD-L1 evaluation was performed blindly and independently for each core (PB). PD-L1 expression was scored semiquantitatively according to the percent of PD-L1 positive tumor cells. The staining scores were given separately for each core according to the percentage of staining (1%–10%, 11–49%, 50%–100%). The mean PD-L1 score of two cores was recorded as a PD-L1 score of the case. Tonsil tissue was used as external control, whereas macrophages were used as an internal control.

2.3. Statistical analysis

Statistical analysis was performed by the SPSS software program version 24.0. (IBM Corp., Armonk, NY, USA). The relation of PD-L1 expression with clinicopathological parameters and histological patterns was investigated using Pearson's χ^2 or Fisher's exact test. Cohen's kappa coefficient was used to compare the agreement between two cores. Overall survival (OS) rates were calculated via the Kaplan-Meier method. Independent samples T-test was used to assess the relationship between age, tumor size, and PD-L1 expression. P values < 0.05 were considered as statistically significant.

3. Results

PD-L1 expression was identified in 41.4% (53/128) of the cases at $\geq 1\%$ cut-off. The positivity rate was 23.5% at $> 10\%$, and 14.1% at $\geq 50\%$ cut-off values. PD-L1 expression was significantly more common in high grade (solid and/or micropapillary) predominant tumors at all cut-off values (≥ 1 (P = 0.14), > 10 (P = 0.03), ≥ 50 (P = 0.01)). We found that there was a greater frequency of tumor size with PD-L1 expression (P = 0.048). However, no clinicopathologic variable correlated with age, gender, lymph node metastasis, pleural invasion, stage, lymphovascular invasion, spread through air spaces (STAS) (P > 0.05), and overall survival (Table 1). As mentioned in the materials-methods section, only one tissue sample/one core was taken from 9 cases (7%). Three of them were positive with PD-L1 (5.6%, 3/53). Since the purpose of our study was to investigate the difference in staining rates between two cores, we excluded these 3 cases from the study. Forty-three of the positive cases (86%, 43/50) was sharing PD-L1 expression on both cores (cut-off value $\geq 1\%$). In 30 cases, the PD-L1 expression rate in both cores was at the same cut-off value (69%, 30/42). Thirteen cases were expressing PD-L1 at different cut-off values though (31%, 13/42) (Figure 1-1a, 1b). However, 7 cases were positive in only one core (14%, 7/50) (Figure 1-2a, 2b). In many of these, the positive core was at a 1%-10% cut-off value (5/7). Others were at a cut-off value of 11%-50% (2/7). Table 2 provides further

Table 1. Relationship of PD-L1 expression with the clinicopathological features of the cases

Variables	PD-L1 $\geq 1\%$ N (%)			PD-L1 $>10\%$ N (%)			PD-L1 $\geq 50\%$ N (%)		
	Positive	Negative	P	Positive	Negative	P	Positive	Negative	P
Sex									
Female	26 (46.5%)	30 (53.5%)	0.309	13 (23.3%)	43 (76.7%)	0.894	9 (16.1%)	47 (83.9%)	0.564
Male	27 (37.5%)	45 (62.5%)		16 (21.7%)	58 (78.3%)		9 (12.4%)	63 (87.5%)	
T Stage									
T1	35 (38.1%)	52 (61.9%)	0.694	15 (17.3%)	72 (82.7%)	0.16	9 (10.4%)	78 (89.6%)	0.78
>T1	18 (55%)	23 (45%)		14 (34.2%)	27 (65.8%)		9 (22%)	32 (78%)	
N Stage									
N0	32 (36.8%)	55 (63.2%)	0.122	18 (20.7%)	69 (79.3%)	0.439	12 (13.8%)	75 (86.2%)	0.898
N1 + N2	21 (51.3%)	20 (48.7%)		11 (26.9%)	30 (73.1%)		6 (14.7%)	35 (85.3%)	
Stage									
I	36 (40%)	54 (60%)	0.619	20 (22.3%)	70 (77.7%)	0.857	11 (12.3%)	79 (87.7%)	0.357
>I	17 (45%)	21 (55%)		9 (23.7%)	29 (76.3%)		7 (18.5%)	31 (81.5%)	
Pleural invasion									
Absent	31 (42%)	43 (58%)	0.896	21 (28.4%)	53 (71.6%)	0.07	12 (66.7%)	6 (33.3%)	0.412
Present	22 (40.8%)	32 (59.2%)		8 (14.9%)	46 (85.1%)		62 (56.4%)	48 (43.6%)	
Venous and lymphatic invasion									
Absent	31 (46.5%)	38 (53.5%)	0.382	18 (27.7%)	48 (72.7%)	0.316	11 (61.2%)	7 (38.8%)	0.508
Present	22 (37.3%)	37 (62.7%)		11 (17.8%)	51 (82.2%)		58 (52.7%)	52 (47.3%)	
STAS									
Absent	23 (46.9%)	25 (53.1%)	0.247	14 (29.2%)	34 (70.8%)	0.173	8 (16.7%)	40 (83.3%)	0.512
Present	30 (37.7%)	50 (62.5%)		15 (18.8%)	65 (81.2%)		10 (12.5%)	70 (87.5%)	
Dominant pattern									
Low grade	31 (34.5%)	59 (65.5%)	0.014	15 (16.5%)	76 (83.5%)	0.03	8 (6.9%)	82 (93.1%)	0.01
High grade	22 (41.6%)	31 (58.4%)		14 (37.9%)	23 (62.1%)		10 (26.4%)	28 (73.6%)	
Age	Median age (range): 63.2 (32-86))				P = 0.98				
Tumor size	Median size (Range): 2.61 (1.4-8 cm)				P = 0.048				
Overall survival (median) (60 moths)	PDL1 (+): 64 moths. PDL1 (-): 54 moths.				P = 0.59				

details and cut-offs of the PD-L1 expression on both cores for each case.

3.1. PD-L1 staining and histological patterns

A total of 247 tissue cores were obtained from 128 cases. The distribution of histological patterns in these cores was as follows: 99 acinar (Figure 2-1a), 88 solid (Figure 2-1b, 2-2a, 2-2b), 32 papillary, 21 micropapillary, 5 lepidic pattern, and 2 mucinous adenocarcinomas. Among these, the most frequent positive PD-L1 rate was included micropapillary (66.7%, 14/21) and solid patterns (59.2%, 51/88). Subtype groups with the least frequent PD-L1 expression included papillary (40.6%, 14/21) and

acinar (19.4%, 18/99) subtypes. PD-L1 positivity was not seen in the lepidic pattern (0%, 0/5) and mucinous adenocarcinomas (0%, 0/2). We found that there was a greater frequency of PD-L1 expression with high-grade histological patterns (solid and micropapillary) compared with the low-intermediate grade histological patterns (lepidic, acinar, papillary) ($P = 0.001$) (Table 3).

Although in a few cases negativity is observed in one core, according to Cohen's test overall agreement between two cores were 'strong' for all cut-off values (respectively 84%, 84%, and 81%) [25] ($k \geq 1\%$: 0.843, $k > 10\%$: 0.848, $k \geq 50\%$: 0.815) (Table 4).




Figure 1. Heterogenous staining pattern samples with PD-L1. 1A: Negative for PD-L1. 1B: Positive with PD-L1. 2A: First core with 5% staining with PD-L1 in micropapillary pattern. 2B: Second core negative for PD-L1 in acinar pattern.

4. Discussion

PD1/PD-L1 receptor-ligand binding is a dominant immune checkpoint pathway, which is known to contribute to tumor immune evasion in several cancer types particularly NSCLC [26,27]. Thus, immune checkpoint inhibitors represent an important breakthrough in cancer treatment and have demonstrated to be highly effective in many tumor types [28,29]. Recently, the U.S. Food and Drug Administration (FDA) approved an antiPD1 drug, as a single chemotherapeutic agent as first-line therapy in patients with tumors expressing PD-L1 in at least 50% of neoplastic cells and second-line therapy with or without chemotherapy combination in patients with more than 1% PD-L1 expression [6,30]. IHC analysis of PD-L1 expression is being used to identify patients who may benefit from PD1/PD-L1 inhibitors [13]. However, heterogeneous staining characteristics of PD-L1 may give rise to false-negativity especially in small biopsy samples [31]. In this study, we aimed to provide a more accurate histological

pattern-based approach to intratumoral heterogeneity of PD-L1 expression in lung adenocarcinomas.

As is well-known, most lung adenocarcinomas exhibit mixed histological patterns. In 2011, the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society proposed a new histological classification for lung adenocarcinomas [32]. This classification recognizes the major histological patterns (lepidic, acinar, papillary, solid, and micropapillary) and variants (mucinous, colloid, enteric, and fetal). Lung adenocarcinomas are labeled according to the predominant histological pattern after this classification [21]. Among these histological patterns, solid and micropapillary patterns have a worse prognosis than lepidic, acinar, and papillary patterns [33,34].

The present immunohistochemical study examined 128 resected lung adenocarcinomas in order to evaluate the heterogeneous expression of PD-L1 between different parts of the tumors and correlations with histological




Figure 2. 1A: PD-L1 staining in acinar pattern. 1B: PD-L1 staining in solid pattern. 2A: 100% positive staining of PD-L1 in solid pattern ($\geq 50\%$ cut-off). 2B: Higher magnification ($\times 20$).

patterns and clinicopathological parameters and potential prognostic impact of PD-L1 expression. Our overall PD-L1 expression rate was 43.4% at $>1\%$ cut-off, and 14.1% at $> 50\%$ cut-off values. Similar results have been obtained in some other studies [20,35]. Moreover, in some series showed a higher percentage of PD-L1 positive cases than we have found [13,14]. This may be due to macroscopic sampling conditions due to delayed/impaired fixation since all cases are resection specimens or may be attributable to the retrospective nature of this study. Gagne et al. demonstrated that specimens containing fewer than 100 tumor cells or older than 3 years may lead to an underestimation of PD-L1 status [36]. At this point, almost half of our cases were older than 3 years. However, all specimens were prepared in the same laboratory with the same standards, and they were reevaluated by the same pulmonary pathologists. Thus, the results of our study, especially the comparison of the cores, can be considered relatively robust. Another relevant finding with the poor prognosis was that the majority of cases with PD-L1 expression results had a larger tumor size. PD-L1 expressing tumors can reach larger diameters than the others. Similar results have been

obtained regarding tumor size and PD-L1 expression in lung adenocarcinomas [37]. In addition, the same study showed that PD-L1 expression was also associated with male gender, smoke, lymph node metastasis, EGFR wild-type status, KRAS mutations, and overall survival [37]. However, we did not find any significant relationship between age, sex, lymph node metastasis, pleural invasion, lymphovascular invasion, STAS, and PD-L1 expression. Also, no significant correlation was found with overall survival; the follow-up periods of the cases were rather short (our mean follow-up time: 62 months). Therefore, a longer follow-up period may be necessary for a more accurate evaluation.

Another interesting finding was the significant correlation among dominant histological patterns and PD-L1 expression. That is the PD-L1 expression rate increases as the tumor differentiation decreases. Song et al. correlated the PD-L1 expression and clinicopathologic features in 404 lung adenocarcinoma patients, and they showed the relation between solid predominant subtype and PD-L1 staining [38]. Similar results have been found in two different studies. In these studies, PD-L1 expression

Table 2. Histologic patterns and staining rates of positive cases with PD-L1.

Case no	1st core pattern	2nd core pattern	1st core PD-L1 score	2nd core PD-L1 score
1	Solid	Solid	3%	3%
2	Micropapillary	Acinar	5%	0%
3	Micropapillary	Solid	40%	40%
4	Acinar	Acinar	5%	2%
5	Acinar	Acinar	2%	2%
6	Micropapillary	Micropapillary	10%	10%
7	Solid	Acinar	30%	0%
8	Solid	Solid	30%	10%
9	Solid	*	30%	*
10	Solid	Solid	5%	5%
11	Solid	Solid	2%	2%
12	Solid	Acinar	100%	30%
13	Papillary	Papillary	3%	3%
14	Micropapillary	Acinar	3%	0%
15	Solid	*	3%	*
16	Micropapillary	Papillary	2%	2%
17	Papillary	Papillary	2%	5%
18	Solid	Acinar	10%	5%
19	Micropapillary	Micropapillary	3%	1%
20	Solid	Micropapillary	5%	30%
21	Micropapillary	Acinar	20%	0%
23	Solid	Solid	70%	80%
23	Acinar	Acinar	7%	2%
24	Solid	Solid	1%	0%
25	Solid	Acinar	80%	20%
26	Solid	Papillary	5%	0%
27	Solid	Solid	0%	5%
28	Papillary	*	2%	*
29	Papillary	Solid	5%	10%
30	Solid	Papillary	100%	100%
31	Acinar	Acinar	100%	100%
32	Solid	Solid	60%	50%
33	Solid	Solid	50%	60%
34	Solid	Acinar	100%	80%
35	Solid	Solid	5%	5%
36	Solid	Micropapillary	100%	50%
37	Micropapillary	Solid	60%	30%
38	Solid	Solid	80%	80%
39	Papillary	Papillary	2%	2%
40	Acinar	Micropapillary	30%	40%
41	Acinar	Acinar	80%	80%
42	Papillary	Papillary	80%	80%

Table 2. (Continued).

43	Solid	Solid	5%	5%
44	Solid	Solid	5%	5%
45	Acinar	Acinar	3%	0
46	Solid	Solid	30%	50%
47	Solid	Solid	50%	50%
48	Acinar	Acinar	5%	20%
49	Solid	Solid	30%	60%
50	Solid	Papillary	5%	1%
51	Solid	Solid	100%	100%
52	Solid	Solid	10%	5%
53	Solid	Solid	60%	70%

*Single core studied cases.

Table 3. PD-L1 staining rates in all cores (119 [double cores] ×2+9 [single cores]) = 247) between low- and high-grade histologic patterns.

	Negative	> 1%	> 10%	≥ 50%	Total	P
Lepidic + acinar + papillary	105 (70%)	19 (41.3%)	4 (20%)	8 (25.8%)	136 (54.9%)	0.001
Micropapillary + solid + mucinous adenocarcinoma	45 (30%)	27 (58.7%)	16 (80%)	23 (74.2%)	111 (45.1%)	
Total	150 (100%)	46 (100%)	20 (100%)	31 (100%)	247 (100%)	

in tumor cells has a correlation with a high histological grade and solid subtype, likewise our results [39,40]. Furthermore, another aim of this study was to analyze the staining differences between different cores. Inside of the positive cases, 14% of them were one core negative. Therefore, taking two different samples from different parts of tumor samples has increased PD-L1 positivity rate in our series. Munari et al. built tissue microarrays with 5 cores per case from 268 cases and compared PD-L1 staining results in the cores with the results obtained by using whole tumor sections [41]. According to their study, 3 or 4 cores are necessary to reach the lowest number of false-negative cases at both cut-offs as 1% and 50%. However, the size of the cores in their study was 1 mm, whereas those included in the present study were 4 mm. Furthermore, most of both core positive cases (69%, 29/42) were positive in the same cut-off values. Nevertheless, 31% (13/42) of them were positive at different cut-offs. This finding highlights the heterogeneity of PD-L1 staining also in our series. Haragan et al. quantified the heterogeneity by comparing different samples from the same tumor at different scales/magnifications; they found intra-tumoral heterogeneity rate decreases if the sections are examined at high power as 78% at small-scale and 46% at large-scale [42]. The primary objective of many studies in the literature is to minimize the number of false-negative cases to ensure that all eligible patients benefit from immunotherapy. In this context, the

second question of our study was whether we could relate this heterogeneous staining with histological patterns of lung adenocarcinomas and predict the positivity rate of PD-L1 expression according to the histological patterns of the tumor. Our data indicate histological patterns of lung adenocarcinoma is related to the PD-L1 expression. In our one core unstained cases, 75% of unstained cores had low/intermediate grade (acinar/papillary) histologic patterns (62.5% acinar, 25% solid, 12.5% papillary patterns). Likewise, the PD-L1 expression rate was significantly higher in solid and micropapillary patterns as compared with acinar, lepidic, and papillary patterns. Two recent studies also showed similar findings; according to their results, PD-L1 positivity was seen mostly in solid/micropapillary patterns in lung adenocarcinoma cases [40,43]. These findings were consistent with another study, which reported an association between PD-L1 expression and histological patterns in pulmonary adenocarcinomas [44].

Finally, PD-L1 expression rates between two cores have shown a strong agreement according to the Cohen test ($k = 0,843$). Although, the remaining 25% of cases had a noncompliance though. If we look at the staining rates of one core unstained cases, none of them was staining higher than 50%. These results leading to results of a higher number of biopsies may increase the number of positive cases, especially in low expression rates, in other words, obtaining additional cores may help to better assess

Table 4. Concordance between cores at different cut-offs.

1% cut-off					
	2nd core				
1st core		Negative	≥ %1	Total	κ 0.843
	Negative	67 (98.5%)	1 (1.5%)	68 (100%)	
	≥%1	8 (16%)	43 (84%)	51 (100%)	
	Total	75 (63%)	44 (37%)	119 (100%)	
10% cut-off					
	2nd core				
1st core		Negative	≥ %1	Total	κ 0.848
	Negative	91 (97%)	3 (3%)	94 (100%)	
	≥%1	3 (12%)	22 (88%)	25 (100%)	
	Total	94 (79%)	25 (21%)	119 (100%)	
50% cut-off					
	2nd core				
1st core		Negative	≥ %1	Total	κ 0.815
	Negative	101 (96%)	2 (4%)	105 (100%)	
	≥%1	3 (19%)	13 (81%)	16 (100%)	
	Total	104 (87.3%)	15 (12.7%)	119 (100%)	

the PD-L1 status. [45]. Haragan et al. say that increasing quantities of tissue for assessment will clearly improve the accuracy, but in fact, even a whole tissue section might still not be representative of the entire tumor [42].

This study has some limitations. First, the PD-L1 expression of the cores was not compared with the whole tumor sections. However, as we obtained two 4-mm tissue cores from each tumor, the samples can be considered as clinically representative biopsies. Second, this is a retrospective study, and preanalytical issues or long archival period may affect the PD-L1 expression status [16]. However, an updated analysis of the Keynote-010 trial study [46], the authors compared the PD-L1 expression status in archival versus newly collected tumor samples. According to their results, the distributions of PD-L1 expression levels (≥ 1% and ≥ 50%) were similar among both archival (60% and 45%, respectively) and newly collected (55% and 45%) tumor samples.

5. Conclusion

This study reflects the correlation between histological patterns and staining heterogeneity of PD-L1 expression

in lung adenocarcinomas. This heterogeneous staining may lead to false negativity in some cases especially in small biopsy samples. The tumors showing solid or micropapillary patterns had more frequent PD-L1 expression when compared to acinar, papillary, and lepidic patterns. According to our results, obtaining more samples from tumors will increase the accuracy of PD-L1 status and solid and/or micropapillary areas may be favored for PD-L1 testing if the tumor has.

Acknowledgments/disclaimers/conflict of interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval: This study has been approved by the Koç University ethics committee (Decision no: 2016. 290. IRB2.147)

The preliminary data of this study were presented during the 27th National Pathology Congress in Turkey, Antalya, November March 15 to 18, 2017.

References

1. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013; 499: 214-218. doi: org/10.1038/nature12213
2. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N et al. Non-small-cell lung cancer. *Nature Reviews Disease Primers* 2015; 1 (15009). doi: org/10.1038/nrdp.2015.9

3. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR et al. Cancer treatment and survivorship statistics, 2019. *A Cancer Journal for Clinicians* 2019; 69: 363-385. doi: org/10.3322/caac.21565
4. Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. *Oncotarget* 2017; 8 (30): 50209-50220. doi: 10.18632/oncotarget.16854
5. Chang L, Hui Y, Qianqian L, Haiquan C, Yuan L et al. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. *Frontiers Oncology* 2019; 9: 1116. doi: 10.3389/fonc.2019.01116
6. Gubens MA, Davies M. NCCN Guidelines Updates: New immunotherapy strategies for improving outcomes in non-small cell lung cancer. *The Journal of the National Comprehensive Cancer Network* 2019; 17: 574-578. doi: org/10.6004/jnccn.2019.5005
7. Chen F, Zhuang X, Lin L, Yu P, Wang Y et al. New horizons in tumor microenvironment biology: challenges and opportunities. *BMC Medical* 2015; 13: 45. doi: 10.1186/s12916-015-0278-7
8. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. *Trends in Molecular Medicine* 2015; 21 (1): 24-33. doi: org/10.1016/j.molmed.2014.10.009
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 2006; 29; 313(5795):1960-1964. doi: 10.1126/science.1129139
10. Okazaki T, Honjo T. PD-1 and PD-L1 ligands: From discovery to clinical application. *International Immunology* 2007; 19: 813-824. doi: org/10.1093/intimm/dxm057
11. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. *Cancer Immunology Immunotherapy* 2007; 56 (5): 739-745. doi: org/10.1007/s00262-006-0272-1
12. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. *European Journal of Surgical Oncology* 2015; 41: 450-456. doi: org/10.1016/j.ejso.2015.01.020
13. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *The New England Journal of Medicine* 2016; 375: 1823-1833. doi: org/10.1056/NEJMoa1606774
14. Gagné A, Enlow W, Pigeon MA, Orain M, Turcotte S et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays. *The American Journal of Surgical Pathology* 2018; 42: 687-694. doi: org/10.1097/PAS.0000000000001013
15. Gradecki SE, Grange JS, Stelow EB. Concordance of PD-L1 expression between core biopsy and resection specimens of non-small cell lung cancer. *The American Journal of Surgical Pathology* 2018; 42: 1090-1094. doi: org/10.1097/PAS.0000000000001085
16. Gagné A, Wang E, Bastien N, Orain M, Desmeules P et al. Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing recommendations. *Journal of Thoracic Oncology* 2019; 14: 2062-2070. doi: org/10.1016/j.jtho.2019.08.2503
17. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. *Journal of Thoracic Oncology* 2017; 12: 208-222. doi: org/10.1016/j.jtho.2016.11.2228
18. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. *Annals of Oncology* 2016; 27: 147-153. doi: org/10.1093/annonc/mdv489
19. Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. *Modern Pathology* 2017; 30: 340-349. doi: org/10.1038/modpathol.2016.186
20. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. *Clinical Lung Cancer* 2015; 16: 385-390. doi: org/10.1016/j.clcc.2015.03.008
21. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. *Journal of Thoracic Oncology* 2015; 10:1243-1260. doi:org/10.1097/JTO.0000000000000630
22. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Modern Pathology* 2012; 25(8): 1117-1127 doi: org/10.1038/modpathol.2012.58
23. Chen Z, Li M, Ma K, Shang G, Liang J et al. Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. *Cancer Medicine* 2020; 9 (2): 517-529. doi: org/10.1002/cam4.2726
24. Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. *Modern Pathology* 2016; 9 (2): 517-529. doi: 10.1002/cam4.2726
25. McHugh ML. Interrater reliability: The kappa statistic. *Biochemica Medica* 2012; 22: 276-282. doi: org/10.11613/bm.2012.031

26. Jing W, Li M, Zhang Y, Teng F, Han A et al. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. *OncoTargets and Therapy* 2016; 9: 489-502. doi: org/10.2147/OTT.S94993
27. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annual Review of Immunology* 2008; 26: 677-704. doi: org/10.1146/annurev.immunol.26.021607.090331
28. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. *International Immunology* 2015; 27:39-46. doi: org/10.1093/intimm/dxu095
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *The New England Journal of Medicine* 2012; 366:2443-2454. doi: org/10.1056/NEJMoa1200690
30. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet* 2016; 387: 1540-1550. doi: org/10.1016/S0140-6736(15)01281-7
31. Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P et al. Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples. *Clinical Lung Cancer* 2017; 18: 682-691.e5. doi: org/10.1016/j.clcc.2017.04.014
32. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K et al. International Association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma - an executive summary. *Proceedings of the American Thoracic Society* 2011; 8:381-385. doi: org/10.1513/pats.201107-042ST
33. Motono N, Matsui T, Machida Y, Usuda K, Uramoto H. Prognostic significance of histologic subtype in p Stage I lung adenocarcinoma. *Medical Oncology* 2017; 34 (6): 100. doi: 10.1007/s12032-017-0962-x
34. Oki T, Aokage K, Nomura S, Tane K, Miyoshi T et al. Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung. *Journal of Cancer Research and Clinical Oncology* 2020. doi: org/10.1007/s00432-020-03158-1
35. Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. *Journal of Thoracic Oncology* 2018; 13: 1113-1120. doi: org/10.1016/j.jtho.2018.04.017
36. Gagné A, Wang E, Bastien N, Orain M, Desmeules P et al. Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing recommendations. *Journal of Thoracic Oncology* 2019; 14: 2062-2070. doi: org/10.1016/j.jtho.2019.08.2503
37. Li H, Xu Y, Wan B, Song Y, Zhan P et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: A meta-analysis of 50 studies with 11,383 patients. *Translational Lung Cancer Research* 2019; 8: 429-449. doi: org/10.21037/tlcr.2019.08.04
38. Song P, Wu S, Zhang L, Zeng X, Wang J. Correlation between PD-L1 expression and clinicopathologic features in 404 patients with lung adenocarcinoma. *Interdisciplinary Sciences, Computational Life Sciences* 2019; doi: org/10.1007/s12539-019-00329-8
39. Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R et al. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. *Virchows Archiv* 2019; 474 (2): 159-168. doi: 10.1007/s00428-018-2483-1
40. Driver BR, Miller RA, Miller T, Deavers M, Gorman B et al. Programmed death ligand-1 (pd-l1) expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. *The Archives of Pathology & Laboratory Medicine* 2017; 141 (11): 1529-1532. doi: org/10.5858/arpa.2017-0028-OA
41. Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. *Journal of Thoracic Oncology* 2018; 13 (8): 1113-1120. doi: org/10.1016/j.jtho.2018.04.017
42. Haragan A, Field JK, Davies MPA, Escriu C, Gruver A et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. *Lung Cancer* 2019; 134: 79-84. doi: 10.1016/j.lungcan.2019.06.005
43. Ng Kee Kwong F, Laggner U, McKinney O, Croud J, Rice A et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. *Histopathology* 2018; 72 (6): 1024-1032. doi: org/10.1111/his.13466
44. Gagné A, Enlow W, Pigeon M-A, Orain M, Turcotte S et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores. *The American Journal of Surgical Pathology* 2018; 42:687-694. doi: org/10.1097/PAS.0000000000001013
45. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. *JAMA Oncology* 2016; 2: 46-54. doi: org/10.1001/jamaoncol.2015.3638
46. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial. *Annals of Oncology* 2019; 1;30 (2): 281-289. doi: 10.1093/annonc/mdy545. doi: org/10.1093/annonc/mdy545